Journal of Clinical Oncology , 27
Grover, M., Anderson, M., Gupta, R., Haden, M., Hartmark-Hill, J., Morski, L.M., Sarmiento, Dueck, A
Molecular basis and enzymatic properties of glucose 6-phosphate dehydrogenase volendam, leading to chronic nonspherocytic anemia, granulocyte dysfunction, and increased susceptibility to infections
An emerging and highly promising strategy involves developing multi-target agonists that also engage the glucagon-like insulinotropic polypeptide receptor (GIPR) and/or the glucagon receptor (GCGR) [14, 15]
In some cases, these side effects can be severe enough to lead to dehydration or even kidney failure
Unfortunately, its druggability is low